Last updated 22 days ago

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

730 patients around the world

Available in Chile, United States, Spain

Merck Sharp & Dohme Corp.

7Research sites

730Patients around the world

This study is for people with

Solid tumors

Requirements for the patient

From 18 Years

All Gender

Medical requirements

Sites

Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana

Recruiting

Manzano 343, Recoleta, Región Metropolitana, Santiagobradfordhill.cl/

Clínica Puerto Montt

Recruiting

Calle Panamericana Nte. 400, Puerto Montt, Los Lagos

Oncovida - Santiago

Recruiting

Gral. Holley 2381, Providencia, Región Metropolitana, Santiago

James Lind Centro de Investigación del Cáncer - Temuco

Recruiting

Hochstetter 298, Temuco

Hospital Universitario Central de Asturias

Recruiting

Oviedo, 33011

Hospital General Universitario Gregorio Marañón

Recruiting

C. del Dr. Esquerdo, 46, 28007 Madrid

Hospital Vall de Hebrón

Recruiting

Pg. de la Vall d'Hebron, 119, 129, 08035 Barcelona, Spain

SponsorMerck Sharp & Dohme Corp.

Study typeInterventional

Conditions

Solid tumors

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT04976634